- Home
- IAS vs AUPH Comparison
IAS vs AUPH Comparison
Compare IAS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- AUPH
- Stock Information
- Founded
- IAS 2009
- AUPH 1993
- Country
- IAS United States
- AUPH Canada
- Employees
- IAS N/A
- AUPH N/A
- Industry
- IAS Computer Software: Programming Data Processing
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- IAS Technology
- AUPH Health Care
- Exchange
- IAS Nasdaq
- AUPH Nasdaq
- Market Cap
- IAS 1.5B
- AUPH 1.4B
- IPO Year
- IAS 2021
- AUPH 1999
- Fundamental
- Price
- IAS $8.34
- AUPH $12.81
- Analyst Decision
- IAS Buy
- AUPH Strong Buy
- Analyst Count
- IAS 11
- AUPH 3
- Target Price
- IAS $13.55
- AUPH $12.00
- AVG Volume (30 Days)
- IAS 810.3K
- AUPH 1.6M
- Earning Date
- IAS 11-11-2025
- AUPH 11-06-2025
- Dividend Yield
- IAS N/A
- AUPH N/A
- EPS Growth
- IAS 3014.55
- AUPH N/A
- EPS
- IAS 0.34
- AUPH 0.42
- Revenue
- IAS $569,836,000.00
- AUPH $260,111,000.00
- Revenue This Year
- IAS $14.77
- AUPH $16.92
- Revenue Next Year
- IAS $11.33
- AUPH $14.43
- P/E Ratio
- IAS $24.75
- AUPH $30.61
- Revenue Growth
- IAS 14.39
- AUPH 25.59
- 52 Week Low
- IAS $6.26
- AUPH $6.43
- 52 Week High
- IAS $13.62
- AUPH $12.90
- Technical
- Relative Strength Index (RSI)
- IAS 41.82
- AUPH 68.86
- Support Level
- IAS $8.38
- AUPH $12.06
- Resistance Level
- IAS $8.94
- AUPH $12.82
- Average True Range (ATR)
- IAS 0.25
- AUPH 0.37
- MACD
- IAS -0.09
- AUPH -0.04
- Stochastic Oscillator
- IAS 4.49
- AUPH 93.23
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.